
Nyxoah SA (NYXH) Stock Forecast & Price Target
Nyxoah SA (NYXH) Analyst Ratings
Bulls say
Nyxoah is poised for continued success as its product gains momentum in the U.S. market and with the pending completion of its ACCCESS study in 2026/2027, which could lead to label expansion. It has already exceeded initial expectations with 15 U.S. implants and 35 VAC approvals, and with a €77M financing secured, the company has the resources to continue its growth trajectory. Q3 revenues of €2.0M were in-line with expectations, showing solid performance and potential for increased profitability.
Bears say
Nyxoah is in a strong position with a successful 4Q25, but there are concerns about its long-term sustainability and potential competition in the sleep-disordered breathing market. The recent personnel changes provide a positive outlook, but there is still uncertainty surrounding the company's ability to drive consistent repeat orders and truly capture the market potential. Additionally, financial metrics such as revenue and profitability may not be able to fully support the company's valuation in the long run.
This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.
Nyxoah SA (NYXH) Analyst Forecast & Price Prediction
Start investing in Nyxoah SA (NYXH)
Order type
Buy in
Order amount
Est. shares
0 shares